Vasopharm taps investors for €20M to fund PhIII trial of brain injury treatment

Nick Paul Taylor Vasopharm has emerged from talks with investors armed with €20 million ($ 22 million) to hustle its treatment for traumatic brain injury through Phase III. The ...

Abingworth tees up a unique, $105M co-development fund for PhIII deals

John Carroll The international team at Abingworth likes investing in co-development programs, backing two companies that specialize in taking on the risk and cost of Phase III in exchange ...

Crippled by 2 deaths, Zafgen says obesity drug cut weight in PhIII

John Carroll With its clinical development program for a new obesity drug in limbo following the unexplained deaths of two patients, Zafgen reported today that the troubled Phase III ...

Acorda bags PhIII Parkinson’s drug in $363M Biotie buyout

John Carroll FierceBiotech News

Eleven Bio faces cash crunch as lead drug flunks another PhIII

John Carroll FierceBiotech News

Cardiorentis bags $60M as PhIII nears end; J&J backs HIV player; Novartis nears Horsham sale

Nick Paul Taylor Our top stories in this week's EuroBiotech Report involve the transfer of more than $ 100 million (€92 million) from the wallets of investors to the bank ...

Cardiorentis raises $60M as PhIII heart failure trial nears completion

Nick Paul Taylor Cardiorentis has raised CHF 60 million ($ 60 million). The investment bolsters the biotech's bank balance at a time when it is nearing the end of a Phase III trial ...

Landmark $1.9B-plus deal for Seres includes PhIII support

John Carroll FierceBiotech News

Chimerix shares crash as antiviral flops and deaths spike in first PhIII challenge

John Carroll High hopes for Chimerix's antiviral turned into a bad case of data shock Monday morning after the biotech revealed that brincidofovir had failed its first Phase III ...

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

John Carroll The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015. FierceBiotech News

Feds clamp a hold on Forum’s PhIII Alzheimer’s study following GI events

John Carroll The FDA has slammed the brakes on the late-stage Alzheimer's development program for encenicline after investigators reported a "small" number of serious ...

UPDATED: On the ropes, GlaxoSmithKline admits to another PhIII debacle

John Carroll GlaxoSmithKline, which recruited more than 16,000 patients in a monumental postapproval effort to distinguish Breo Ellipta by improving the mortality rates of high-risk ...
Page 1 of 912345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS